Clinical Trial Update: CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial evaluating CMP-001 in combination with nivolumab versus nivolumab monotherapy in advanced or unresectable melanoma was terminated, with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• CMP-001
• nivolumab (nivolumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Melanoma, Advanced Melanoma | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2025-09-05